4basebio Seeks Shareholder Approval for Capital Raise of at Least £15 Million

4basebio shareholders will vote November 6, 2026, on share issuance authorities for a proposed capital raise of at least £15 million. Resolutions would authorize directors to allot new ordinary shares and disapply statutory pre-emption rights for the placing, subscription and retail offer. New shares would be issued at 515 pence each, an 8.4% discount to the October 14 closing price. Proceeds would support commercial expansion, manufacturing capacity and working capital, extending the cash runway to H2 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BASEBIO plc published the original content used to generate this news brief via (Ref. ID: 202610150200PR_NEWS_PRUKDSCX_0003) on October 15, 2026, and is solely responsible for the information contained therein. (C)